Terumo Aortic Announces First Commercial Implant of “Upon Request” RelayPro Endovascular Device in the United States

January 14, 2022

Terumo Aortic today announced the first commercial implant of a RelayPro Thoracic Stent-Graft System developed through its “Upon Request” program in the United States.

With the “Upon Request” program, there are approximately 2000 stent-graft configurations approved by the US Food and Drug Administration (FDA) which allow physicians significantly more solutions to better fit the anatomical needs of each individual patient. These configurations offer devices that can taper from a larger diameter on top of the device and tapering down by as much as 18mm at the bottom, or a smaller diameter on top and flaring by as much as 18mm larger on the bottom.

The first commercial implant of an “Upon Request” RelayPro device was undertaken by Mazin Foteh MD, Vascular Surgeon, Heart Hospital of Austin, Texas. Dr Foteh commented: “The opportunity to tailor the stent-graft system to precisely match the anatomy of the patient was hugely valuable as it allowed me to accommodate a big gap of the proximal and distal diameters with a single device. This first procedure was very successful, the device performed exactly as expected, and the patient is making a good recovery.”

Paul Kuznik, President of Terumo Aortic North America commented: “This first “Upon Request” implant represents another significant milestone for our RelayPro range and emphasises our commitment to delivering the most comprehensive device portfolio within the aortic space and our vision for individualised treatment.”

RelayPro is the only lower profile device with a Non-Bare Stent design available in the United States to treat aneurysms and penetrating atherosclerotic ulcers, and received FDA approval in 2021; it is integral to Terumo Aortic’s market leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.